NYSE · LLY
Eli Lilly and Company
$1,431.41+$57.71 (+4.2%)
Eli Lilly and Company’s quoted price is above the reported 52-week high. The range and quote may have different update times.
Loading market information…
OTC · GRTX · USD
Stock price, earnings
Quote as of Aug 3, 2026, 06:11 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Galera Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 42.83% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Galera Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:59 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -$0.06+99.92% vs estimate |
| $0.00 |
| Q2 2024 | Aug 14, 2024 | -$0.07+99.91% vs estimate | $0.00-100.0% vs estimate |
|---|
THE ANALYST VIEW
9 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,431.41+$57.71 (+4.2%)
Eli Lilly and Company’s quoted price is above the reported 52-week high. The range and quote may have different update times.
$279.10+$3.90 (+1.42%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 0.7% below the high.
$297.56+$6.77 (+2.33%)
AbbVie Inc.’s quoted price is above the reported 52-week high. The range and quote may have different update times.
$3.34-$0.02 (-0.6%)
X4 Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 30.85% below the high.
$46.20-$0.63 (-1.33%)
Spruce Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 64.19% below the high.
$0.94+$0.00 (+0.4%)
Biofrontera Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.66% below the high.
$0.37+$0.00 (+0.11%)
Pasithea Therapeutics Corp.’s quoted price sits in the lower half of its reported 52-week range, 82.04% below the high.
$0.43-$0.00 (-1.07%)
Ensysce Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.57% below the high.
